Evidence map›Paper›PMID 37887106›Full record

ArticleBiosensors2023

Extract2Chip-Bypassing Protein Purification in Drug Discovery Using Surface Plasmon Resonance.

Ana C F Paiva, Ana R Lemos, Philipp Busse, Madalena T Martins, Diana O Silva, Micael C Freitas, Sandra P Santos, Filipe Freire, Evelyne J Barrey, Xavier Manival and 7 more

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Cobalt oxide modified screen-printed carbon electrode for electrochemical detection of high blood pressure treating drug: reserpine.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Ana C F PaivaiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0002-3637-7702
Ana R LemosiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0002-3987-4771
Philipp BusseiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0001-8728-017X
Madalena T MartinsiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.
Diana O SilvaiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0002-3225-4756
Micael C FreitasiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0001-7468-3471
Sandra P SantosiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0001-9153-5550
Filipe FreireiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0002-5310-0668
Evelyne J BarreyMerck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Xavier ManivalIMoPA, CNRS, Université de Lorraine, F-54000 Nancy, France.ORCID 0000-0002-7717-7096
Lisa KoetznerMerck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Timo HeinrichMerck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Ansgar WegenerMerck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.ORCID 0009-0005-5737-7460
Ulrich GrädlerMerck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Tiago M BandeirasiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0001-6089-6089
Daniel SchwarzMerck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
Pedro M F SousaiBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.ORCID 0000-0002-6672-3610
Instituto de Biologia Experimental e Tecnológica · PTMerck (Germany) · DECentre National de la Recherche Scientifique · FR

Funding

Associate Laboratory LS4FUTURE 702 LA/P/0087/2020Fundação para a Ciência e Tecnologia/Ministério da Ciência, 700 Tecnologia e Ensino Superior, iNOVA4Health 701 UIDB/04462/2020Fundação para a Ciência e Tecnologia/Ministério da Ciência, 700 Tecnologia e Ensino Superior, iNOVA4Health 701 UIDP/04462/2020
6 · The paper itself

Abstract

Modern drug discovery relies on combinatorial screening campaigns to find drug molecules targeting specific disease-associated proteins. The success of such campaigns often relies on functional and structural information of the selected therapeutic target, only achievable once its purification is mastered. With the aim of bypassing the protein purification process to gain insights on the druggability, ligand binding, and/or characterization of protein-protein interactions, herein, we describe the Extract2Chip method. This approach builds on the immobilization of site-specific biotinylated proteins of interest, directly from cellular extracts, on avidin-coated sensor chips to allow for the characterization of molecular interactions via surface plasmon resonance (SPR). The developed method was initially validated using Cyclophilin D (CypD) and subsequently applied to other drug discovery projects in which the targets of interest were difficult to express, purify, and crystallize. Extract2Chip was successfully applied to the characterization of Yes-associated protein (YAP): Transcriptional enhancer factor TEF (TEAD1) protein-protein interaction inhibitors, in the validation of a ternary complex assembly composed of Dyskerin pseudouridine synthase 1 (DKC1) and RuvBL1/RuvBL2, and in the establishment of a fast-screening platform to select the most suitable NUAK family SNF1-like kinase 2 (NUAK2) surrogate for binding and structural studies. The described method paves the way for a potential revival of the many drug discovery campaigns that have failed to deliver due to the lack of suitable and sufficient protein supply.

Indexed as

Drug DiscoverySurface Plasmon ResonanceChromatography, AffinityProtein BindingProteinsProteinsdrug discoveryExtract2Chipprotein biotinylationsurface plasmon resonance

Identifiers

PMID37887106
PMCPMC10605449
OpenAlexW4387364547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.